专利检索 ap:"Erik Meredith" 第 3 页

21.

发明授权
Heterobicyclic carboxamides as inhibitors for kinases 有权
标题翻译：异环碳酰胺作为激酶抑制剂

公开(公告)号：US08242125B2

公开(公告)日：2012-08-14

申请号：US12632396

申请日：2009-12-07

申请人： Gerald David Artman, III , Jason Matthew Elliott , Nan Ji , Donglei Liu , Fupeng Ma , Nello Mainolfi , Erik Meredith , Karl Miranda , James J. Powers , Chang Rao

发明人： Gerald David Artman, III , Jason Matthew Elliott , Nan Ji , Donglei Liu , Fupeng Ma , Nello Mainolfi , Erik Meredith , Karl Miranda , James J. Powers , Chang Rao

IPC分类号： C07D403/12 , C07D403/14 , C07D471/04 , C07D487/04 , C07D487/08 , A61K31/404

CPC分类号： C07D403/12 , A61K31/18 , A61K31/404 , A61K45/06 , C07D403/14 , C07D413/14 , C07D471/04 , C07D487/04 , C07D487/08 , A61K2300/00

摘要： The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumor diseases and ocular neovascular diseases.

摘要翻译： 本发明涉及式（I）的新型有机化合物及其在治疗动物或人体中的用途，包括式I化合物的药物组合物和式I化合物在制备药物组合物中的用途用于治疗蛋白激酶依赖性疾病，特别是增殖性疾病，例如治疗肿瘤疾病和眼睛新生血管疾病。

22.

发明申请
ORGANIC COMPOUNDS 审中-公开
标题翻译：有机化合物

公开(公告)号：US20120142685A1

公开(公告)日：2012-06-07

申请号：US12594728

申请日：2008-04-04

申请人： Markus Rolf Dobler , Charles Francis Jewell, JR. , Erik Meredith , Lauren G. Monovich , Sarah Siska , Anette Von Matt , Maurice Van Eis , Taeyoung Yoon , Christoph Gaul , Michael Paul Capparelli

发明人： Markus Rolf Dobler , Charles Francis Jewell, JR. , Erik Meredith , Lauren G. Monovich , Sarah Siska , Anette Von Matt , Maurice Van Eis , Taeyoung Yoon , Christoph Gaul , Michael Paul Capparelli

IPC分类号： A61K31/5377 , C07D471/10 , A61K31/444 , A61P7/10 , A61P9/04 , A61P35/00 , A61P3/04 , A61P3/10 , C07D471/04 , A61K31/496

CPC分类号： C07D471/04

摘要： The present invention provides a compound formula I: (formula I) said compound is inhibitor of selective subset of kinases belonging to the AGC or calmodulin kinase family, such as for example MARK1/2/3, PKD-1/2/3, PKN-1/2, CDK-9, CaMKII, ROCK-I/II, inhibitors of histone deacetylase (HDAC) phosphorylation, or inhibitors of other kinases. Finally, the present invention also provides a pharmaceutical composition.

摘要翻译： 本发明提供式I化合物：（式I）所述化合物是属于AGC或钙调蛋白激酶家族的激酶选择性亚型的抑制剂，例如MARK1 / 2/3，PKD-1/2/3，PKN -1/2，CDK-9，CaMKII，ROCK-I / II，组蛋白脱乙酰酶（HDAC）磷酸化抑制剂或其他激酶抑制剂。最后，本发明还提供药物组合物。

23.

发明申请
Use of an Adrenal Hormone-Modifying Agent 审中-公开
标题翻译：使用肾上腺激素修饰剂

公开(公告)号：US20140171392A1

公开(公告)日：2014-06-19

申请号：US14079018

申请日：2013-11-13

申请人： Qi-Ying Hu , Gary Michael Ksander , Erik Meredith , Lauren G. Monovich , Julien Papillon , Christoph Schumacher

发明人： Qi-Ying Hu , Gary Michael Ksander , Erik Meredith , Lauren G. Monovich , Julien Papillon , Christoph Schumacher

IPC分类号： C07F9/6506 , C07D487/04

CPC分类号： C07F9/6506 , A61K31/4188 , A61K31/55 , A61P5/00 , C07D487/04

摘要： The present invention relates to a method of treating a disease or disorder characterised by increased stress hormone levels and/or decreased androgen hormone levels in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): wherein n is 1 or 3; R is hydrogen or —C(O)N(Ra)(Rb) wherein Ra and Rb are independently —(C1-C4) alkyl, or —(C1-C4) alkyl-(C5-C7) aryl, wherein each of Ra and Rb is optionally substituted by —(C1-C4) alkoxy; R1, R2, and R3, are independently hydrogen, halogen, cyano or —(C6-C10) aryl, wherein said —(C6-C10) aryl is optionally substituted by halogen, with the proviso that no more than one of R1, R2, and R3 is hydrogen; and R4 and R5 are hydrogen; or a pharmaceutically acceptable salt thereof.

摘要翻译： 本发明涉及治疗受试者特征为增加的应激激素水平和/或降低雄激素激素水平的疾病或病症的方法，包括向受试者施用治疗有效量的由式（I）表示的化合物：其中 n为1或3; 其中R a和R b独立地为 - （C 1 -C 4）烷基或 - （C 1 -C 4）烷基 - （C 5 -C 7）芳基），其中R a为并且R b任选被 - （C 1 -C 4）烷氧基取代; R 1，R 2和R 3独立地是氢，卤素，氰基或 - （C 6 -C 10）芳基，其中所述 - （C 6 -C 10）芳基任选被卤素取代，条件是不大于1个，，R3为氢; R4和R5是氢; 或其药学上可接受的盐。

24.

发明授权
Use of an adrenal hormone-modifying agent 有权
标题翻译：使用肾上腺激素调节剂

公开(公告)号：US08609862B2

公开(公告)日：2013-12-17

申请号：US13521548

申请日：2011-01-13

申请人： Qi-Ying Hu , Gary Michael Ksander , Erik Meredith , Lauren G. Monovich , Julien Papillon , Christoph Schumacher

发明人： Qi-Ying Hu , Gary Michael Ksander , Erik Meredith , Lauren G. Monovich , Julien Papillon , Christoph Schumacher

IPC分类号： A61K31/4188 , C07D235/02

CPC分类号： C07F9/6506 , A61K31/4188 , A61K31/55 , A61P5/00 , C07D487/04

摘要： The present invention relates to a method of treating a disease or disorder characterised by increased stress hormone levels and/or decreased androgen hormone levels in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): wherein n is 1 or 3; R is hydrogen or —C(O)N(Ra)(Rb) wherein Ra and Rb are independently —(C1-C4)alkyl, or —(C1-C4)alkyl-(C5-C7)aryl, wherein each of Ra and Rb is optionally substituted by —(C1-C4)alkoxy; R1, R2, and R3, are independently hydrogen, halogen, cyano or —(C6-C10) aryl, wherein said —(C6-C10)aryl is optionally substituted by halogen, with the proviso that no more than one of R1, R2, and R3 is hydrogen; and R4 and R5 are hydrogen; or a pharmaceutically acceptable salt thereof.

摘要翻译： 本发明涉及治疗受试者特征为增加的应激激素水平和/或降低雄激素激素水平的疾病或病症的方法，包括向受试者施用治疗有效量的由式（I）表示的化合物：其中 n为1或3; 其中R a和R b独立地为 - （C 1 -C 4）烷基或 - （C 1 -C 4）烷基 - （C 5 -C 7）芳基），其中R a为并且R b任选被 - （C 1 -C 4）烷氧基取代; R 1，R 2和R 3独立地是氢，卤素，氰基或 - （C 6 -C 10）芳基，其中所述 - （C 6 -C 10）芳基任选被卤素取代，条件是不大于1个，，R3为氢; R4和R5是氢; 或其药学上可接受的盐。

25.

发明授权
Heterobicyclic carboxamides as inhibitors for kinases 有权

公开(公告)号：US08431584B2

公开(公告)日：2013-04-30

申请号：US13488760

申请日：2012-06-05

申请人： Gerald David Artman, III , Jason Matthew Elliott , Nan Ji , Donglei Liu , Fupeng Ma , Nello Mainolfi , Erik Meredith , Karl Miranda , James J. Powers , Chang Rao

发明人： Gerald David Artman, III , Jason Matthew Elliott , Nan Ji , Donglei Liu , Fupeng Ma , Nello Mainolfi , Erik Meredith , Karl Miranda , James J. Powers , Chang Rao

IPC分类号： C07D487/04 , C07D487/08 , A61K31/404

CPC分类号： C07D403/12 , A61K31/18 , A61K31/404 , A61K45/06 , C07D403/14 , C07D413/14 , C07D471/04 , C07D487/04 , C07D487/08 , A61K2300/00

摘要： The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumor diseases and ocular neovascular diseases.

26.

发明申请
USE OF AN ADRENAL HORMONE-MODIFYING AGENT 有权
标题翻译：使用ADRENAL HORMONE-MODIFYING AGENT

公开(公告)号：US20120295888A1

公开(公告)日：2012-11-22

申请号：US13521548

申请日：2011-01-13

申请人： Qi-Ying Hu , Gary Michael Ksander , Erik Meredith , Lauren G. Monovich , Julien Papillon , Christoph Schumacher

发明人： Qi-Ying Hu , Gary Michael Ksander , Erik Meredith , Lauren G. Monovich , Julien Papillon , Christoph Schumacher

IPC分类号： A61K31/4188 , A61K31/55 , A61P9/04 , A61P5/00 , A61P9/00 , A61P43/00 , A61P5/06 , A61P3/00 , C07D487/04 , A61P21/00

CPC分类号： C07F9/6506 , A61K31/4188 , A61K31/55 , A61P5/00 , C07D487/04

摘要： The present invention relates to a method of treating a disease or disorder characterised by increased stress hormone levels and/or decreased androgen hormone levels in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): wherein n is 1 or 3; R is hydrogen or —C(O)N(Ra)(Rb) wherein Ra and Rb are independently —(C1-C4)alkyl, or —(C1-C4)alkyl-(C5-C7)aryl, wherein each of Ra and Rb is optionally substituted by —(C1-C4)alkoxy; R1, R2, and R3, are independently hydrogen, halogen, cyano or —(C6-C10) aryl, wherein said —(C6-C10)aryl is optionally substituted by halogen, with the proviso that no more than one of R1, R2, and R3 is hydrogen; and R4 and R5 are hydrogen; or a pharmaceutically acceptable salt thereof.

摘要翻译： 本发明涉及治疗受试者特征为增加的应激激素水平和/或降低雄激素激素水平的疾病或病症的方法，包括向受试者施用治疗有效量的由式（I）表示的化合物：其中 n为1或3; 其中R a和R b独立地为 - （C 1 -C 4）烷基或 - （C 1 -C 4）烷基 - （C 5 -C 7）芳基），其中R a为并且R b任选被 - （C 1 -C 4）烷氧基取代; R 1，R 2和R 3独立地是氢，卤素，氰基或 - （C 6 -C 10）芳基，其中所述 - （C 6 -C 10）芳基任选被卤素取代，条件是不大于1个，，R3为氢; R4和R5是氢; 或其药学上可接受的盐。